Renascience Inc. (JP:4889)

:4889

4889

Renascience Inc.

RESEARCH TOOLSreports

Renascience Inc. (4889) Price & Analysis

0 Followers

4889 Stock Chart & Stats

¥1436.00

-¥9.00(-2.89%)

At close: Jan 08 4:00 PM EST

¥1436.00

-¥9.00(-2.89%)

Day’s Range― - ―

52-Week Range¥868.00 - ¥3,310.00

Previous CloseN/A

Volume77.30K

Average Volume (3M)312.67K

Market Cap

¥23.12B

Enterprise Value¥18.91B

Total Cash (Recent Filing)¥1.67B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta0.79

Next Earnings

May 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.21

Shares Outstanding13,776,900

10 Day Avg. Volume205,420

30 Day Avg. Volume312,670

Financial Highlights & Ratios

PEG Ratio-0.82

Price to Book (P/B)7.74

Price to Sales (P/S)100.40

P/FCF Ratio-75.20

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA zero-debt FY2025 position and a ¥1.72B equity base provide durable financial flexibility, lowering insolvency risk and giving management options to fund operating deficits, R&D or strategic moves without immediate external leverage, improving medium-term resilience.

Very High Gross MarginA ~97% gross margin indicates strong unit economics or pricing power that, if sustained, supports durable profitability even at modest sales levels. High gross margins create structural room to absorb SG&A or R&D spend and can enable rapid operating leverage if revenue stabilizes or grows.

Net Income Turned Positive In FY2025Returning to net profitability with ¥113.4M in FY2025 and a modest positive ROE (~6.6%) signals a potential structural inflection. If management sustains margins and controls costs, this shift can translate into consistent earnings generation and better capital allocation over the next several quarters.

Bears Say

Persistent Negative Operating And Free Cash FlowDespite reported net income, the company continues to burn cash with negative operating and free cash flow, creating a structural funding requirement. Ongoing cash deficits raise the likelihood of equity issuance, external financing or cutbacks, constraining long-term investment and strategic flexibility.

Declining Revenue TrendA weakening revenue trend undermines the sustainability of high margins and any profitability gains. Falling top-line across periods means operating leverage is limited and suggests market demand or commercial execution issues that could persist, making future margin and earnings stability uncertain.

Uneven Historical Profitability And Reliance On One-off DriversFY2025's profit appears against a multi-year loss history and notes of non-recurring drivers, indicating earnings quality risks. Such inconsistency reduces forecasting confidence and raises the chance that current profits may not persist without sustained operational improvement or recurring revenue growth.

4889 FAQ

What was Renascience Inc.’s price range in the past 12 months?

Renascience Inc. lowest stock price was ¥868.00 and its highest was ¥3310.00 in the past 12 months.

What is Renascience Inc.’s market cap?

Renascience Inc.’s market cap is ¥23.12B.

When is Renascience Inc.’s upcoming earnings report date?

Renascience Inc.’s upcoming earnings report date is May 13, 2026 which is in 38 days.

How were Renascience Inc.’s earnings last quarter?

Renascience Inc. released its earnings results on Feb 13, 2026. The company reported -¥5.21 earnings per share for the quarter, missing the consensus estimate of N/A by -¥5.21.

Is Renascience Inc. overvalued?

According to Wall Street analysts Renascience Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Renascience Inc. pay dividends?

Renascience Inc. does not currently pay dividends.

What is Renascience Inc.’s EPS estimate?

Renascience Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Renascience Inc. have?

Renascience Inc. has 13,776,900 shares outstanding.

What happened to Renascience Inc.’s price movement after its last earnings report?

Renascience Inc. reported an EPS of -¥5.21 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.626%.

Which hedge fund is a major shareholder of Renascience Inc.?

Currently, no hedge funds are holding shares in JP:4889

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Renascience Inc.

Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.